
Anti-vascular endothelial growth factor (anto-VEGF) monotherapy is inadequate in patients with age-related macular degeneration (AMD). However, by adding an anti-platelet-derived growth factor (anti-PDGF) drug to the anti-VEGF regimen, treatment is enhanced by preventing the development of fibrosis thus improving visual outcomes, according to Usha Chakravarthy, MBBS, PhD.
 

.png)


